Assessment of Pain During Intramuscular Injection Delay in Adult Psychiatry

Last updated: March 3, 2024
Sponsor: Centre hospitalier de Ville-Evrard, France
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

first injection delay and second injection delay

Clinical Study ID

NCT04784572
10477M-EVADOULIM
  • Ages > 18
  • All Genders

Study Summary

Since psychiatry is still too often confronted with a dichotomy between psyche and soma, the assessment of pain and anxiety at RMI is still rarely done (Willer et al., 1982). The objective of this exploratory study is to evaluate the influence of pharmacological factors (type of injected molecules, injection frequency, injection site, treatment duration, treatment dose, time since last injection) and individual about the pain perceived when injecting antipsychotic therapy (diagnosis, sex, age, weight, duration of illness, level of anxiety, psychiatric and somatic comorbidity, insight). In the future, this study will develop a suitable procedure to limit pain and anxiety during RMI. Taking these dimensions into account will probably allow a better compliance of patients for this type of care, and thus a decrease in the number of relapses in the long term.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients (Males, Females)
  • Over the age of 18
  • Hospitalized or outpatient
  • Patient affiliated with social security, State Medical Aid (AME)
  • With prescription of antipsychotic delay by intramuscular injection
  • French language mastered
  • Given oral consent to pass the self-assessment scales

Exclusion

Exclusion Criteria:

  • Patients on long-term analgesic treatment, daily
  • Patients with chronic pain with or without analgesic treatment
  • Patient not communicating
  • Pregnant woman, parturint and nursing mother
  • Person deprived of liberty by judicial or administrative decision
  • Minor and person subject to legal protection: guardianship or curatorship

Study Design

Total Participants: 393
Treatment Group(s): 1
Primary Treatment: first injection delay and second injection delay
Phase:
Study Start date:
January 22, 2021
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Ch Ville Evrard

    Neuilly-sur-Marne, 93330
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.